[ad_1]
IvelinRadkov
- AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) stated {that a} Phase 3 examine of their antibody drug conjugate, or ADC, datopotamab deruxtecan didn’t present it was capable of considerably lengthen lives versus the chemotherapy drug docetaxel.
- While the examine’s outcomes for total survival favored the drug, also called Dato-DXd, they didn’t attain statistical significance, based on a press release.
- The data did present, nonetheless, a 2.3 month enchancment for Dato-DXd sufferers with non-squamous non-small cell lung cancer, or NSCLC, with total survival of 14.6 months, in contrast with 12.3 months for sufferers given docetaxel.
- In sufferers with squamous NSCLC, no total survival enchancment was noticed.
- Shares of AstraZeneca closed 3% decrease on Monday following the information.
More on AstraZeneca, Daiichi Sankyo, and so forth.
[ad_2]
Source: Seekingalpha